Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.

A Ullman, N Svedmyr

Department of Clinical Pharmacology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal experiments to produce a more prolonged bronchodilator effect than currently available beta 2 adrenoceptor agonists. It was studied in eight adult asthmatic patients. Each patient received on separate test days salbutamol 200 micrograms and salmeterol 50, 100, and 200 micrograms according to a randomised, double blind, crossover design. FEV1, peak expiratory flow (PEF), heart rate, blood pressure, and tremor were recorded in the clinic for six hours after drug inhalation; PEF was recorded for a further six hours at home. All three doses of salmeterol produced peak increases in FEV1 (mean 0.5-0.8 l) and PEF (71-100 l/min) similar to those produced by salbutamol 200 micrograms (0.5 l and 74 l/min). After salbutamol FEV1 and PEF had returned to baseline within six hours, but after all three doses of salmeterol more than half of the maximum bronchodilator effect remained after 12 hours. The effects of salbutamol and the two lower doses of salmeterol (50 and 100 micrograms) on cardiovascular measurements and on tremor were similar, whereas after salmeterol 200 micrograms there was a small decrease in diastolic blood pressure and an increase in heart rate and tremor. Thus inhaled salmeterol has a long acting bronchodilator action in asthmatic patients. This effect may be of value in the treatment of asthma, particularly in patients with nocturnal symptoms.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Luks, A. M., Swenson, E. R. (2008). Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness. Chest 133: 744-755 [Abstract] [Full Text]  
• Wadbo, M., Lofdahl, C-G., Larsson, K., Skoogh, B.E., Tornling, G., Arwestrom, E., Bengtsson, T., Strom, K. (2002). Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 20: 1138-1146 [Abstract] [Full Text]  
• KIPS, J. C., PAUWELS, R. A. (2001). Long-acting Inhaled beta 2-Agonist Therapy in Asthma. Am. J. Respir. Crit. Care Med. 164: 923-932 [Full Text]  
• Johnson, M., Rennard, S. (2001). Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD. Chest 120: 258-270 [Abstract] [Full Text]  
• Peters, J. I., Shelledy, D. C., Jones, A. P. Jr., Lawson, R. W., Davis, C. P., LeGrand, T. S. (2000). A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma. Chest 118: 313-320 [Abstract] [Full Text]  
• Guhan, A R, Cooper, S, Oborne, J, Lewis, S, Bennett, J, Tattersfield, A E (2000). Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55: 650-656 [Abstract] [Full Text]  
• Groeben, H., Emala, C. (1999). Is {beta}-Adrenergic-Mediated Airway Relaxation of Salmeterol Antagonized by Its Solvent Xinafoic Acid?. Chest 115: 1678-1683 [Abstract] [Full Text]  
• NELSON, H. S., BERKOWITZ, R. B., TINKELMAN, D. A., EMMETT, A. H., RICKARD, K. A., YANCEY, S. W. (1999). Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma. Am. J. Respir. Crit. Care Med. 159: 1556-1561 [Abstract] [Full Text]  
• Chervinsky, P., Goldberg, P., Galant, S., Wang, Y., Arledge, T., Welch, M. B., Stahl, E. (1999). Long-term Cardiovascular Safety of Salmeterol Powder Pharmacotherapy in Adolescent and Adult Patients With Chronic Persistent Asthma: A Randomized Clinical Trial. Chest 115: 642-648 [Abstract] [Full Text]  
• Teschemacher, A., Lemoine, H. (1999). Kinetic Analysis of Drug-Receptor Interactions of Long-Acting beta 2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl Cyclase. J. Pharmacol. Exp. Ther. 288: 1084-1092 [Abstract] [Full Text]  
• Taylor, D., Jensen, M., Aikman, S., Harris, J., Barnes, P., O'Connor, B. (1997). Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Crit. Care Med. 156: 1731-1737 [Abstract] [Full Text]  
• Wilding, P., Clark, M., Coon, J. T., Lewis, S., Rushton, L., Bennett, J., Oborne, J., Cooper, S., Tattersfield, A. E (1997). Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 314: 1441-1441 [Abstract] [Full Text]  
• (1997). Using {beta}2-stimulants in asthma. DTB 35: 1-4 [Abstract] [Full Text]  
• Busse, W. W. (1996). Long- and Short-Acting {beta}2-Adrenergic Agonists: Effects on Airway Function in Patients With Asthma. Arch Intern Med 156: 1514-1520 [Abstract]  
• D'Alonzo, G. E., Nathan, R. A., Henochowicz, S., Morris, R. J., Ratner, P., Rennard, S. I. (1994). Salmeterol Xinafoate as Maintenance Therapy Compared With Albuterol in Patients With Asthma. JAMA 271: 1412-1416 [Abstract]  
• Kemp, J. P. (1993). Approaches to Asthma Management: Realities and Recommendations. Arch Intern Med 153: 805-812 [Abstract]